ALKS Alkermes (ALKS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001520262
Congress · 1Form 144 · 7
Insider buyers, 180 days
0
Funds added, last quarter
229
13F, latest reported quarter
Conversions, 180 days
19
Codes C/M, not in net · $2.9M priced
What the filings say about ALKS
Insiders, 180 days
-$5.9M net sold
6 sellers · 18% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-29
Planned sales (Form 144), 90 days
$3.8M
7 notices
Alkermes insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Alkermes plc. insiders sold a net $5.9M of stock across 80 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Sep 3, 2026.
- The trade is 0.9% of the 221,388 shares held after it.
- No other insider sold within 30 days.
- 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CLO, Alkermes, Inc. Gaffin David Joseph sold about $83.5K of ALKS under a 10b5-1 plan on Oct 2, 2026; 229 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 3, 2026.
- The trade is 0.9% of the 223,422 shares held after it.
- 2 other insiders sold within 30 days.
- 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CLO, Alkermes, Inc. Gaffin David Joseph sold about $97.7K of ALKS under a 10b5-1 plan on Sep 3, 2026; 2 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.Context
- 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Aug 3, 2026.
- The trade is 13.8% of the 65,389 shares held after it.
- 3 other insiders sold within 30 days.
- 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP R&D, Chief Medical Officer Hopkinson Craig C. sold about $422.9K of ALKS under a 10b5-1 plan on Sep 1, 2026; 3 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Mar 2, 2026.
- The trade is 6.7% of the 102,857 shares held after it.
- 3 other insiders sold within 30 days.
- 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Commercial Officer Nichols Christian Todd sold about $340.0K of ALKS on Aug 17, 2026; 3 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Mar 2, 2026.
- The trade is 0.6% of the 102,193 shares held after it.
- 3 other insiders sold within 30 days.
- 229 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Commercial Officer Nichols Christian Todd sold about $33.0K of ALKS on Aug 17, 2026; 3 other insiders sold within 30 days and 229 funds added in the latest 13F quarter.80 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$5.9M over 180 days
-$3.8M over 90 days
below 80% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
229 funds bought in last quarter
more than 92% of Pharma & Biotech
Revenue
-5.2% year over year
below 62% of Pharma & Biotech
Margin
16.4% net margin
more than 86% of Pharma & Biotech
Buybacks
$27.7M repurchased, FY to 2026-06-30
below 52% of Pharma & Biotech
Short interest
11.5% of the float short (float per yahoo 2026-10-26) · 6.3 days to cover · settled 2026-09-30
more than 74% of Pharma & Biotech
What changed in the last 30 days
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Oct 2EVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $83.5K under a 10b5-1 plan (Oct 2)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Officer Gaffin David Joseph filed to sell $83.5K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch ALKS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+42.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ALKS: institutional holders (13F)
13F holdings, latest reported quarter
29,235,739 sh
$1.5B
10,012,267 sh
$524.6M
9,490,818 sh
$497.3M
9,160,575 sh
$480.0M
7,515,025 sh
$393.7M
Congress trades in ALKS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-29 · disclosed 13 days later
$1,001 - $15,000
Bought 2026-07-30 · disclosed 36 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ALKS planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Gaffin David Joseph
Filed 2026-10-02
$83.5K
Gaffin David Joseph
Filed 2026-09-03
$97.7K
Hopkinson Craig C.
Filed 2026-09-01
$422.9K
Nichols Christian Todd
Filed 2026-08-17
$372.9K
Hopkinson Craig C.
Filed 2026-08-03
$437.2K
ALKS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$7.2M position · as of 2026-05-31
4.5%
Invesco S&P SmallCap Health Care ETF
$4.9M position · as of 2026-05-31
3.7%
ERSHARES GLOBAL ENTREPRENEURS
$1.5M position · as of 2026-06-30
3.4%
Nuveen Small/Mid Cap Value Fund
$2.9M position · as of 2026-06-30
2.2%
AXS Knowledge Leaders ETF
$953.6K position · as of 2026-06-30
2.1%
Nuveen Small Cap Value Opportunities Fund
$6.5M position · as of 2026-06-30
2.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
16 registered trials, 8 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
4
Phase 2
2 active
7
Phase 3
5 active
2
Not applicable
0 active
1
Multi-phase
1 active
What changed recently
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
2026-10-10 · Completion moved 2028-06 → 2030-06
PHASE2,PHASE3
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathi
2026-09-26 · Recruiting → Active Not Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Alkermes, Inc. Political Action Committee
Cycle 2026 · $158K spent
$121.4K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.9M
$12.6M
$3.5M
+43%
+25%
2024
$10.1M
$14.6M
$3.9M
+46%
-7%
2023
$9.4M
$9.0M
$4.0M
+41%
-6%
2022
$10.3M
$8.3M
$4.2M
+31%
-10%
2021
$8.8M
$11.2M
$2.9M
+17%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.9M sold by insiders over 180 days, 229 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $3.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ALKS financials
Revenue growth
-5.2%
XBRL, annual
Net margin
16.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.7B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ALKS
| FY Dec 2025 | $1.5B |
| FY Dec 2024 | $1.6B |
| FY Dec 2023 | $1.7B |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | $1.2B |
| Jun 2026 | $496.0M |
| Mar 2026 | $392.9M |
| Dec 2025 | $384.5M |
| Sep 2025 | $394.2M |
| Jun 2025 | $390.7M |
| Mar 2025 | $306.5M |
| Dec 2024 | $430.0M |
| Sep 2024 | $378.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+4.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ALKS
| FY Dec 2025 | +16.4% |
| FY Dec 2024 | +23.6% |
| FY Dec 2023 | +21.4% |
| FY Dec 2022 | -14.2% |
| FY Dec 2021 | -4.1% |
| Jun 2026 | +0.1% |
| Mar 2026 | -16.9% |
| Dec 2025 | +12.8% |
| Sep 2025 | +21.0% |
| Jun 2025 | +22.3% |
| Mar 2025 | +7.3% |
| Dec 2024 | +34.1% |
| Sep 2024 | +24.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$221.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ALKS
| FY Dec 2025 | $480.3M |
| FY Dec 2024 | $405.6M |
| FY Dec 2023 | $353.3M |
| FY Dec 2022 | -$17.2M |
| FY Dec 2021 | $73.7M |
| Jun 2026 | $137.0M |
| Mar 2026 | -$169.8M |
| Dec 2025 | $170.1M |
| Sep 2025 | $84.4M |
| Jun 2025 | $137.2M |
| Mar 2025 | $88.7M |
| Dec 2024 | $180.6M |
| Sep 2024 | $73.3M |
At each fiscal year end
Single quarter
Debt to equity
0.83x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ALKS
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.20x |
| FY Dec 2023 | 0.24x |
| FY Dec 2022 | 0.28x |
| FY Dec 2021 | 0.27x |
| Jun 2026 | 0.83x |
| Mar 2026 | 0.86x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.17x |
| Jun 2025 | 0.18x |
| Mar 2025 | 0.19x |
| Dec 2024 | 0.20x |
| Sep 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.17x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ALKS
| FY Dec 2025 | n/a |
| FY Dec 2024 | 1.52x |
| FY Dec 2023 | 1.38x |
| FY Dec 2022 | 0.07x |
| FY Dec 2021 | 0.34x |
| Jun 2026 | 0.17x |
| Mar 2026 | 0.17x |
| Dec 2025 | n/a |
| Sep 2025 | 1.87x |
| Jun 2025 | 1.80x |
| Mar 2025 | 1.79x |
| Dec 2024 | 1.52x |
| Sep 2024 | 1.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+3.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ALKS
| FY Dec 2025 | +14.7% |
| FY Dec 2024 | +27.5% |
| FY Dec 2023 | +31.7% |
| FY Dec 2022 | -14.7% |
| FY Dec 2021 | -4.4% |
| Jun 2026 | +3.9% |
| Mar 2026 | +9.4% |
| Dec 2025 | +14.7% |
| Sep 2025 | +22.4% |
| Jun 2025 | +24.0% |
| Mar 2025 | +25.5% |
| Dec 2024 | +27.5% |
| Sep 2024 | +25.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ALKS
| FY Dec 2025 | +10.6% |
| FY Dec 2024 | +17.5% |
| FY Dec 2023 | +17.4% |
| FY Dec 2022 | -7.9% |
| FY Dec 2021 | -2.4% |
| Jun 2026 | +2.0% |
| Mar 2026 | +4.8% |
| Dec 2025 | +10.6% |
| Sep 2025 | +15.1% |
| Jun 2025 | +15.6% |
| Mar 2025 | +16.8% |
| Dec 2024 | +17.5% |
| Sep 2024 | +15.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+2.9%
operating income after a 32.1% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ALKS
| FY Dec 2025 | +16.2% |
| FY Dec 2024 | +28.3% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +7.9% |
| Jun 2026 | +2.9% |
| Mar 2026 | +5.2% |
| Dec 2025 | +16.2% |
| Sep 2025 | +23.3% |
| Jun 2025 | +26.1% |
| Mar 2025 | +26.1% |
| Dec 2024 | +28.3% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+4.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ALKS
| FY Dec 2025 | +14.4% |
| FY Dec 2024 | +26.2% |
| FY Dec 2023 | +26.9% |
| FY Dec 2022 | -0.4% |
| FY Dec 2021 | +6.4% |
| Jun 2026 | +4.3% |
| Mar 2026 | +7.2% |
| Dec 2025 | +14.4% |
| Sep 2025 | +20.2% |
| Jun 2025 | +21.8% |
| Mar 2025 | +23.7% |
| Dec 2024 | +26.2% |
| Sep 2024 | +18.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
116.63x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ALKS
| FY Dec 2025 | 19.57x |
| FY Dec 2024 | 13.31x |
| FY Dec 2023 | 13.27x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 137.89x |
| Mar 2026 | 39.29x |
| Dec 2025 | 19.57x |
| Sep 2025 | 14.93x |
| Jun 2025 | 13.82x |
| Mar 2025 | 15.88x |
| Dec 2024 | 13.31x |
| Sep 2024 | 14.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.4B
market value at close 2026-10-27 on 2026-07-23 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ALKS
| FY Dec 2025 | $4.2B |
| FY Dec 2024 | $4.7B |
| FY Dec 2023 | $4.5B |
| FY Dec 2022 | $4.3B |
| FY Dec 2021 | $3.7B |
| Jun 2026 | $9.7B |
| Mar 2026 | $7.1B |
| Dec 2025 | $4.2B |
| Sep 2025 | $4.6B |
| Jun 2025 | $4.5B |
| Mar 2025 | $5.3B |
| Dec 2024 | $4.7B |
| Sep 2024 | $4.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield ALKS
| FY Dec 2025 | +10.4% |
| FY Dec 2024 | +8.7% |
| FY Dec 2023 | +7.6% |
| FY Dec 2022 | -0.4% |
| FY Dec 2021 | +2.0% |
| Jun 2026 | +2.5% |
| Mar 2026 | +3.8% |
| Dec 2025 | +10.4% |
| Sep 2025 | +9.9% |
| Jun 2025 | +10.2% |
| Mar 2025 | +9.0% |
| Dec 2024 | +8.7% |
| Sep 2024 | +6.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -82%, PEG needs growth
PEG, trailing ALKS
| FY Dec 2025 | n/a |
| FY Dec 2024 | 3.98x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 7.35x |
| Jun 2025 | 0.64x |
| Mar 2025 | n/a |
| Dec 2024 | 3.98x |
| Sep 2024 | 0.24x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.7B | $1.1B |
| Operating income | $254.0M | $420.6M | $414.1M | -$6.1M |
| Net income | $241.7M | $367.1M | $355.8M | -$158.3M |
| EPS (diluted) | 1.43 | 2.17 | 2.10 | -0.97 |
| Operating cash flow | $520.8M | $439.1M | $401.4M | $21.0M |
| Cash | $388.6M | $291.1M | $457.5M | $292.5M |
| Long-term debt | $0 | n/a | $287.7M | $290.3M |
| Buybacks | n/a | $200.3M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
ALKS Stock Sonar score 6/7 axes
Find similar shapesCompareALKS ranks highest on institutional and government (83rd percentile) and profitability (66th), and lowest on insider conviction (9th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ALKS filings, in plain words
Are Alkermes insiders buying or selling ALKS?
In the 180 days to 2026-10-27, Alkermes insiders were net sellers, a net $5.9M across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded ALKS?
Yes. In the year to 2026-10-27, 1 House member disclosed buying ALKS and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29.
Are there planned insider sales of ALKS?
Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $3.8M of stock; the latest, by Gaffin David Joseph, was filed 2026-10-02.
Read the full summary
In the 180 days to 2026-10-27, Alkermes insiders were net sellers of ALKS, a net $5.9M across purchases and sales reported on Form 4 by 6 sellers. 18% of the 17 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying ALKS and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $3.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
